Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Making prevention pay

Nature Biotechnology volume 22, pages 387–391 (2004)Cite this article

Funding for biodefense is spurring new vaccine and anti-infective programs at several biotech companies.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Antibody optimization.
Figure 2: A heteropolymer drug.

References

  1. Anonymous. Vaccines seen as a $10 billion market by 2006. Reuters News Service January 7 (2003).

  2. Cummings, C.A. & Relman, D.A. Using DNA microarrays to study host-microbe interactions. Emerg. Infect. Dis. 6, 513–525 (2000).

    Article  CAS  Google Scholar 

  3. Krieg, A.M. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546–549 (1995).

    Article  CAS  Google Scholar 

  4. Kuroiwa, Y. et al. Cloned transchromosomic calves producing human immunoglobulin. Nat. Biotechnol. 20, 889–894 (2002).

    Article  CAS  Google Scholar 

  5. Fraser, C. A Genomics-based approach to biodefence preparedness. Nature Reviews Genetics 5, 23–33 (2004).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. freelance writer based, New York

    Alan Dove

Authors
  1. Alan Dove
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dove, A. Making prevention pay. Nat Biotechnol 22, 387–391 (2004). https://doi.org/10.1038/nbt0404-387

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0404-387

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing